Pharmacogenomics & Personalized Medicine

期刊全称Pharmacogenomics & Personalized Medicine
期刊缩写PHARMACOGEN PERS MED
涉及主题医学生物遗传学内科学化学生物化学基因基因型病理生物信息学药理学心理学内分泌学精神科肿瘤科外科药物遗传学数学免疫学等位基因物理癌症统计单核苷酸多态性有机化学
期刊介绍

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. In particular, emphasis will be given to: Genomic and proteomic profiling Genetics and drug metabolism Targeted drug identification and discovery Optimizing drug selection & dosage based on patient's genetic profile Drug related morbidity & mortality intervention Advanced disease screening and targeted therapeutic intervention Genetic based vaccine development Patient satisfaction and preference Health economic evaluations Practical and organizational issues in the development and implementation of personalized medicine programs.

期刊ISSNprint: 1178-7066
历年影响因子
2024年 2023年 2022年 2021年 2020年 2019年 2018年 2017年
1.81.92.6063.9123.264000
历年发表/被引量
年份20252024202320222021202020192018201720162015201420132012
发表量12449782155753223311515361711
被引量44112071197110410108216204884564243702089829
h-Index0
自引率0.00%
涉及的研究领域Biochemistry, Genetics and Molecular Biology-Molecular Medicine
中科院2025年分区 ?
大类小类TOP期刊综述期刊
4区4区 药学
WOS期刊分区

JCR学科分类

JCR分区学科名称收录数据库JCR分区分区排名
PHARMACOLOGY & PHARMACYSCIEQ3244/352

JCI学科分类

JCI分区学科名称收录数据库JCI分区分区排名
PHARMACOLOGY & PHARMACYSCIEQ3214/353
期刊主页https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal
投稿网址https://www.dovepress.com/submit_step_1.php
出版商Dove Medical Press
出版国家(地区)New Zealand
出版语言English
每年出版文章数149
Gold OA文章占比98.46%
原创研究文献占比
(排除综述)
87.50%
SCI收录类型

Science Citation Index Expanded (SCIE)

Scopus (CiteScore)

Directory of Open Access Journals (DOAJ)

PubMed链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-7066%5BISSN%5D
平均审稿周期16 Weeks
相关链接

您可以在上述网站查看该期刊的网友互动,及期刊影响力的其它指标。

注:上述信息均来源于网络,仅供查考,如有遗漏或信息错误,欢迎 向我反馈